Email Medtest DX Medtest Headquarters Medtest Facebook Medtest Linkedin

Oxycodone


(Assays)

METHOD

DRI Urine Drug Screening

TECHNICAL INFORMATION

Format: Liquid
Wavelength: 340 nm
Linearity: 1000 ng/mL
Storage Temperature: 2 - 8° C
  • Description
  • Ordering Information
  • Related Products
  • Documentation

Intended Use

The DRI Oxycodone Enzyme Immunoassay is intended for the qualitative and semi-quantitative determination of oxycodone in human urine.

Principle

The DRI® Oxycodone Assay is supplied as a liquid ready-to-use homogeneous enzyme immunoassay. The assay uses specific antibodies that can detect oxycodone and oxymorphone without any significant cross-reactivity to other opiate compounds. The assay is based on competition between a drug labeled with glucose-6-phosphate dehydrogenase (G6PDH), and free drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the specific antibody binds the drug labeled with G6PDH and causes a decrease in enzyme activity. This phenomenon creates a direct relationship between the drug concentration in urine and enzyme activity. The enzyme activity is determined spectrophotometrically at 340 nm by measuring the conversion of nicotinamide adenine dinucleotide (NAD) to NADH.